Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites

European Journal of Surgical Oncology

Volumn 23, Issue 6, 1997, Pages 526-531

  Parsons, Simon L ^a   Watson, Susan A ^a   Steele, Robert J C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Intraperitoneal therapy; Malignant ascites; Metalloproteinase

Indexed keywords

BATIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ASCITES TUMOR; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DYSPNEA; EDEMA; FEVER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG EMBOLISM; MUSCLE WEAKNESS; NAUSEA; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT OUTCOME; VOMITING;

EID: 0031461180     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)93077-8     Document Type: Article

References (21)

1. Parsons SL, Watson SA, Steele RJC. Malignant ascites: a review. Br J Surg 1996; 83: 6-14.
2. Parsons S, Lang M, Steele R. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996; 22: 237-9.
3. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-64.
4. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991; 49: 666-72.
5. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-6.
6. Davies B, Miles D, Happerfield L, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31.
7. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99-106.
8. Davies B, Brown P, East N, Crimmin M, Balkwill F. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing huam ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-91.
9. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726-8.
10. Watson SA, Morris TM, Parsons SL, Steele PB, Brown PB. Therapeutic effect of the matrix metalloproteinase inhibitor Batimastat in a human colorectal cancer ascites model. Br J Cancer 1996; 74: 1354-8.
11. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33.
12. Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4.
13. Brown P, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-74.
14. Brown P. Batimastat (BB-94) Clinical Investigator's Brochure, update to the fourth edition. Oxford: British Biotech. 1994.
15. Appelqvist P, Silvo J, Salmeda L, Kostianien S. On the treatment and prognosis of malignant ascites; is survival time determined when the abdominal paracentesis is needed? J Surg Oncol 1982; 20: 238-42.
16. Ross G, Kessler H, Clair M, Gatenby R, Hartz W, Ross L. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. Am J Roentgenol 1989; 153/6: 1309-11.
17. Markman M. Intraperitoneal chemotherapy as a treatment of ovarian carcinoma: why, how and when? Obstetrical and Gynaecological Survey 1987; 42: 533-9.
18. Taraboletti G, Garofalo A, Belotti D. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8.
19. Dhami M, Bona R. Thrombosis in patients with cancer. Postgraduate Med 1993; 93: 131-40.
20. Senger D, Galli S, Dvorak A, Peruzzi C, Harvey V, Dvorak H. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
21. Unemori E, Ferrara N, Bauer E, Amento E. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cellular Physiol 1992; 153: 557-62.